Abstract
In April 2005, exenatide (Byetta; Amylin/Eli Lilly) was approved by the US FDA as an adjunctive therapy to improve blood-sugar control in patients with type 2 diabetes. It is the first in a new class of drugs that mimic the activity of natural glucoregulatory peptides known as incretins.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Clarithromycin prevents preterm birth and neonatal mortality by dampening alarmin-induced maternal–fetal inflammation in mice
BMC Pregnancy and Childbirth Open Access 20 June 2022
-
Microneedle-array patches loaded with dual mineralized protein/peptide particles for type 2 diabetes therapy
Nature Communications Open Access 24 November 2017
-
Sustained-release study on Exenatide loaded into mesoporous silica nanoparticles: in vitro characterization and in vivo evaluation
DARU Journal of Pharmaceutical Sciences Open Access 04 September 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
Purchase on Springer Link
Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Moller, D. E. New drug targets for type 2 diabetes and the metabolic syndrome. Nature 414, 821–827 (2001).
Goke, R. et al. Exendin-4 is a high potency agonist and truncated exendin-(9–39)-amide an antagonist at the glucagon-like peptide 1-(7–36)-amide receptor of insulin-secreting β-cells. J. Biol. Chem. 268, 19650–19655 (1993).
Joy, S. V. et al. Incretin mimetics as emerging treatments for type 2 diabetes. Ann. Pharmacother. 39, 110–118 (2005).
FDA labelling information [online], <http://www.fda.gov/cder/foi/label/2005/021773lbl.pdf> (2005).
Buse, J. B. et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27, 2628–2635 (2004).
Kendall, D. M. et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28, 1083–1091 (2005).
DeFronzo, R. A. et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28, 1092–1100 (2005).
U.K. Prospective Diabetes Study Group. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 44, 1249–1258 (1995).
Brownlee, M. Biochemistry and molecular cell biology of diabetic complications. Nature 414, 813–820 (2001).
Brownlee, M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54, 1615–1625 (2005).
International Diabetes Federation <http://www.idf.org/>.
American Diabetes Association <http://www.diabetes.org/>.
IMS Health analysis, IMS MIDAS Quantum, MAT (Dec 2004).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Davidson, M., Bate, G. & Kirkpatrick, P. Exenatide. Nat Rev Drug Discov 4, 713–714 (2005). https://doi.org/10.1038/nrd1828
Issue Date:
DOI: https://doi.org/10.1038/nrd1828
This article is cited by
-
Clarithromycin prevents preterm birth and neonatal mortality by dampening alarmin-induced maternal–fetal inflammation in mice
BMC Pregnancy and Childbirth (2022)
-
GLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis
Acta Pharmacologica Sinica (2022)
-
Sustained-release study on Exenatide loaded into mesoporous silica nanoparticles: in vitro characterization and in vivo evaluation
DARU Journal of Pharmaceutical Sciences (2017)
-
Microneedle-array patches loaded with dual mineralized protein/peptide particles for type 2 diabetes therapy
Nature Communications (2017)
-
GSK2374697, a Novel Albumin-Binding Domain Antibody (AlbudAb), Extends Systemic Exposure of Exendin-4: First Study in Humans—PK/PD and Safety
Clinical Pharmacology & Therapeutics (2014)